Cargando…
Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
Lymphoma, which is highly malignant, stems from lymph nodes and lymphoid tissue. Lymphoma cells express programmed death-ligand 1/2 (PD-L1/PD-L2), which binds with programmed cell death 1 protein (PD-1) to establish inhibitory signaling that impedes the normal function of T cells and allows tumor ce...
Autores principales: | Hou, Yong-Zhe, Zhang, Qin, Bai, Hai, Wu, Tao, Chen, Ya-Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011990/ https://www.ncbi.nlm.nih.gov/pubmed/36926390 http://dx.doi.org/10.12998/wjcc.v11.i7.1458 |
Ejemplares similares
-
Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
por: Zheng, Lin-Lin, et al.
Publicado: (2021) -
Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021) -
Systemic adverse effects and toxicities associated with immunotherapy: A review
por: Kichloo, Asim, et al.
Publicado: (2021) -
Immunotherapies in sarcoma: Updates and future perspectives
por: Ghosn, Marwan, et al.
Publicado: (2017) -
Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
por: Grillo, Thais Gagno, et al.
Publicado: (2023)